Cited by 118Blood transfusion and managementTrauma, Hemostasis, Coagulopathy, ResuscitationMaternal and fetal healthcare

The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage–an observational study

Ahmed, S., Harrity, C., Johnson, S., Varadkar, S., McMorrow, S., Fanning, R., Flynn, C. M., O' Riordan, J. M. +1 more·2012·Transfusion Medicine

Abstract

BACKGROUND: Fibrinogen replacement is critical in major obstetric haemorrhage (MOH). Purified, pasteurised fibrinogen concentrate appears to have benefit over cryoprecipitate in ease of administration and safety but is unlicensed in pregnancy. In July 2009, the Irish Blood Transfusion Service replaced cryoprecipitate with fibrinogen. OBJECTIVES: To examine the impact of this externally imposed change on blood product use and clinical outcomes in MOH. METHODS: Women with MOH requiring fibrinogen between 1 January 2009 and 30 June 2011 were identified from an MOH database. Aetiology of MOH, medical treatments, blood product use and clinical outcomes were compared between the cryoprecipitate and fibrinogen groups. RESULTS: Of 21 614 deliveries, 77 cases of MOH were identified. Of the 77 cases, 34 (44%) received cryoprecipitate (n = 14) or fibrinogen concentrate (n = 20). The mean (± SEM) dose utilised was 2.21 ± 0.35 pools of cryoprecipitate and 4 ± 0.8 g of fibrinogen. There was a stronger correlation between the increase in fibrinogen level and dose of fibrinogen (Pearson co-efficient 0.5; P = 0.03) than dose of cryoprecipitate (Pearson co-efficient 0.32; P = 0.3). Mean (± SEM) estimated blood loss (EBL), red cell concentrate (RCC) and Octaplas transfused were greater (but not significantly) in the cryoprecipitate group compared with the fibrinogen group; EBL = 5.2 ± 1.1 vs 3.3 ± 0.5 L (P = 0.1); RCC = 7.2 ± 1.2 vs 5.9 ± 1.0 U (P = 0.4); Octaplas = 4.1 ± 0.7 vs 3.2 ± 0.7 U (P = 0.36), respectively. Haemostasis was secured, and there were no adverse reactions or thrombotic complications. CONCLUSION: Purified virally inactivated fibrinogen concentrate is as efficacious as cryoprecipitate in correcting hypofibrinogenaemia in MOH.

Integrity signals

Registry

Crossref · 10.1111/j.1365-3148.2012.01178.x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ahmed, S., Harrity, C., Johnson, S., Varadkar, S., McMorrow, S., Fanning, R., Flynn, C. M., O' Riordan, J. M., & Byrne, B. M.
Affiliations
  • Coombe Women & Infants University Hospital (IE)
  • Irish Blood Transfusion Service National Blood Centre Dublin Ireland
Corresponding author
Byrne, B. M.
Venue
Transfusion Medicine
Publisher
Wiley
Published
2012-09-20
Volume
22
Issue
5
Pages
344-349
ISSN
  • 0958-7578 (ISSN-L)
  • 1365-3148
OpenAlex
W1853981075
Cited by
118
References
25
Citations by year
2026: 5 · 2025: 3 · 2024: 8 · 2023: 9 · 2022: 3 · 2021: 6 · 2020: 8 · 2019: 7 · 2018: 7 · 2017: 15 · 2016: 12 · 2015: 14 · 2014: 14 · 2013: 6 · 2012: 1
FWCI
7.83
Type
journal article
Language
en
Open access
closed
Locations
  • Transfusion Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
Topics
  • Health Sciences › Medicine › Biochemistry › Blood transfusion and management
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Trauma, Hemostasis, Coagulopathy, Resuscitation
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Maternal and fetal healthcare
Keywords
major obstetric haemorrhage, fibrinogen concentrate, cryoprecipitate, fibrinogen replacement, blood product utilization, estimated blood loss, packed red blood cells, hemostasis, transfusion policy, pregnancy, hypofibrinogenemia, thrombocytopenia, coagulopathy, transfusion safety, thrombotic complications
MeSH terms
Adult, Coagulants, Factor VIII, Female, Fibrinogen, Hemorrhage, Humans, Ireland, Pregnancy, Prospective Studies, Blood Loss, Surgical, Delivery, Obstetric

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review